
Conference Coverage
about 6 hours ago
Next-generation dry eye therapies with Dr Rahul TonkLatest News

New tried-and-true treatments for retinal vein occlusion

Next-generation dry eye therapies with Dr Rahul Tonk

FDA approves DifGen’s generic fluorometholone ophthalmic suspension 0.1% for steroid-responsive anterior segment inflammation

Q&A: KSI-101: A new dual anti-interleukin-6 and anti-VEGF protein for treating macular edema associated with inflammation

The gene therapy shift

Shorts










Ophthalmology Times Digital Edition

Podcasts
Continuing Medical Education
All News

Join Douglas D. Koch, MD, and Liliana Werner, MD, PhD, as they break down acrylic and silicone intraocular lenses, discuss material-specific risks, and explore the future of lens technology in this inaugural episode.

Zarmeena Vendal, MD, discussed the intersections between cataract surgery and glaucoma.

Inder Paul Singh, MD, discusses his practice's approach to office-based surgery.

McCabe, MD, presented alongside P. Dee Stephenson, MD, FACS, for the product theater titled "Know Your Dry Eye: Navigating the Challenges of Real-World Dry Eye Cases."


Most eyes were fluid-free after 24 weeks with visual acuity increases observed in some.

Rahul Tonk, MD, MBA, gives an overview of the cases he discussed during his portion of a segment on refractive surgery.

Risk stratification, patch graft selection, tube repositioning, and multidisciplinary care all play a role in minimizing erosion and protecting long-term outcomes.

Nicole Bajic, MD, outlines key takeaways from her case study involving Descemet membrane detachment occurring in the setting of focal canaloplasty using the Streamline Surgical System.

Pathik P. Amin, OD, FAAO, details his segment of an educational track session on glaucoma at this year's conference.

Across sessions, speakers emphasized that AI is not a replacement for physician judgment.

Shameema Sikder, MD, details a session she presented with Roomasa Channa, MD, at EnVision Summit 2026.

Improved guidance on preservatives and allergens needed to ensure safety.

Real-world data shows systemic immunomodulators beat local steroids for chronic uveitis, cutting glaucoma, cataract, CME, and ERM risks.













































